David William Howells

David William Howells

Auto-generated profile, based on publicly available information

David William Howells

Tasmanian School of Medicine, College of Health and Medicine University of Tasmania Hobart Tasmania Australia

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
NSNathalie Percie Du Sert
Nathalie Percie Du Sert
VHViki Hurst
Viki Hurst
AAAmrita AHLUWALIA
Amrita AHLUWALIA
SASabina Alam
Sabina Alam
MAMarc Avey
Marc Avey
HWHanno Würbel
Hanno Würbel
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the “ARRIVE Essential 10,” which constitutes the minimum requirement, and the “Recommended Set,” which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration (E&E) document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.

14 July 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
NSNathalie Percie Du Sert
Nathalie Percie Du Sert
AAAmrita AHLUWALIA
Amrita AHLUWALIA
SASabina Alam
Sabina Alam
MAMarc Avey
Marc Avey
MBMonya Baker
Monya Baker
HWHanno Würbel
Hanno Würbel
Improving the reproducibility of biomedical research is a major challenge. Transparent and accurate reporting is vital to this process; it allows readers to assess the reliability of the findings and repeat or build upon the work of other researchers. The ARRIVE guidelines (Animal Research: Reporting In Vivo Experiments) were developed in 2010 to help authors and journals identify the minimum information necessary to report in publications describing in vivo experiments. Despite widespread endorsement by the scientific community, the impact of ARRIVE on the transparency of reporting in animal research publications has been limited. We have revised the ARRIVE guidelines to update them and facilitate their use in practice. The revised guidelines are published alongside this paper. This explanation and elaboration document was developed as part of the revision. It provides further information about each of the 21 items in ARRIVE 2.0, including the rationale and supporting evidence for their inclusion in the guidelines, elaboration of details to report, and examples of good reporting from the published literature. This document also covers advice and best practice in the design and conduct of animal studies to support researchers in improving standards from the start of the experimental design process through to publication.

1 January 2014 in The Lancet
Verified
Journal Article
Closed access
ICIain Chalmers
Iain Chalmers
MBMichael B Bracken
Michael B Bracken
BDBen Djulbegovic
Ben Djulbegovic
SGSilvio Garattini
Silvio Garattini
JGJonathan Grant
Jonathan Grant
SOSandy Oliver
Sandy Oliver

17 February 2006 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
VOVictoria E. O'Collins
Victoria E. O'Collins
MMMalcolm R. Macleod
Malcolm R. Macleod
GDGeoffrey Donnan
Geoffrey Donnan
LHLaura L. Horky
Laura L. Horky
BWBart H. van der Worp
Bart H. van der Worp
DHDavid W. Howells
David W. Howells

30 March 2010 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
HWH. Bart van der Worp
H. Bart van der Worp
DHDavid W. Howells
David W. Howells
ESEmily S. Sena
Emily S. Sena
MPMichelle J. Porritt
Michelle J. Porritt
SRSarah Rewell
Sarah Rewell
MMMalcolm R. Macleod
Malcolm R. Macleod
H. Bart van der Worp and colleagues discuss the controversies and possibilities of translating the results of animal experiments into human clinical trials.

1 June 2009 in Stroke
Verified
Journal Article
Closed access
PDF file
MFMarc Fisher
Marc Fisher
GFGiora Feuerstein
Giora Feuerstein
DHDavid W. Howells
David W. Howells
PHPatricia D. Hurn
Patricia D. Hurn
TKThomas A. Kent
Thomas A. Kent
ELEng H. Lo
Eng H. Lo
The initial Stroke Therapy Academic Industry Roundtable (STAIR) recommendations published in 1999 were intended to improve the quality of preclinical studies of purported acute stroke therapies. Although recognized as reasonable, they have not been closely followed nor rigorously validated. Substantial advances have occurred regarding the appropriate quality and breadth of preclinical testing for candidate acute stroke therapies for better clinical translation. The updated STAIR preclinical recommendations reinforce the previous suggestions that reproducibly defining dose response and time windows with both histological and functional outcomes in multiple animal species with appropriate physiological monitoring is appropriate. The updated STAIR recommendations include: the fundamentals of good scientific inquiry should be followed by eliminating randomization and assessment bias, a priori defining inclusion/exclusion criteria, performing appropriate power and sample size calculations, and disclosing potential conflicts of interest. After initial evaluations in young, healthy male animals, further studies should be performed in females, aged animals, and animals with comorbid conditions such as hypertension, diabetes, and hypercholesterolemia. Another consideration is the use of clinically relevant biomarkers in animal studies. Although the recommendations cannot be validated until effective therapies based on them emerge from clinical trials, it is hoped that adherence to them might enhance the chances for success.